Click for best price
Communicable Diseases Drugs Market Size, Share 2024
| Market size in 2023 |
US$ 26560 million
|
Forecast Market size by 2030 |
US$ 65970 million
|
| Growth Rate |
CAGR of 6.9% |
Number of Pages |
123 Pages |
This research report provides a comprehensive analysis of the Communicable Diseases Drugs market, focusing on the current trends, market dynamics, and future prospects. The report explores the global Communicable Diseases Drugs market, including major regions such as North America, Europe, Asia-Pacific, and emerging markets. It also examines key factors driving the growth of Communicable Diseases Drugs, challenges faced by the industry, and potential opportunities for market players.
The global Communicable Diseases Drugs market has witnessed rapid growth in recent years, driven by increasing environmental concerns, government incentives, and advancements in technology. The Communicable Diseases Drugs market presents opportunities for various stakeholders, including Hospital, Clinic. Collaboration between the private sector and governments can accelerate the development of supportive policies, research and development efforts, and investment in Communicable Diseases Drugs market. Additionally, the growing consumer demand present avenues for market expansion.
The global Communicable Diseases Drugs market was valued at US$ 26560 million in 2023 and is projected to reach US$ 65970 million by 2030, at a CAGR of 6.9% during the forecast period.
The Communicable Diseases Treatment market refers to the pharmaceuticals and treatments used for the management and control of infectious diseases that can be transmitted from person to person. This market includes antiviral drugs, antibiotics, vaccines, and other therapies. The Communicable Diseases Treatment market has experienced significant growth due to factors such as the increasing prevalence of infectious diseases, the emergence of new pathogens, and the need for effective treatment options. Key players in the market include pharmaceutical companies, biotechnology firms, and government healthcare agencies. Geographically, the market is diverse, with regions facing different communicable disease burdens.
Key Features:
The research report on the Communicable Diseases Drugs market includes several key features to provide comprehensive insights and facilitate decision-making for stakeholders.
Executive Summary: The report provides overview of the key findings, market trends, and major insights of the Communicable Diseases Drugs market.
Market Overview: The report provides a comprehensive overview of the Communicable Diseases Drugs market, including its definition, historical development, and current market size. It covers market segmentation by Type (e.g., HIV, Influenza), region, and application, highlighting the key drivers, challenges, and opportunities within each segment.
Market Dynamics: The report analyses the market dynamics driving the growth and development of the Communicable Diseases Drugs market. The report includes an assessment of government policies and regulations, technological advancements, consumer trends and preferences, infrastructure development, and industry collaborations. This analysis helps stakeholders understand the factors influencing the Communicable Diseases Drugs market's trajectory.
Competitive Landscape: The report provides an in-depth analysis of the competitive landscape within the Communicable Diseases Drugs market. It includes profiles of major market players, their market share, strategies, product portfolios, and recent developments.
Market Segmentation and Forecast: The report segment the Communicable Diseases Drugs market based on various parameters, such as by Type, region, and by Application. It provides market size and growth forecasts for each segment, supported by quantitative data and analysis. This helps stakeholders identify growth opportunities and make informed investment decisions.
Technological Trends: The report should highlight the key technological trends shaping the Communicable Diseases Drugs market, such as advancements in Type One technology and emerging substitutes. It analyses the impact of these trends on market growth, adoption rates, and consumer preferences.
Market Challenges and Opportunities: The report identify and analyses the major challenges faced by the Communicable Diseases Drugs market, such as technical bottleneck, cost limitations, and high entry barrier. It also highlights the opportunities for market growth, such as government incentives, emerging markets, and collaborations between stakeholders.
Regulatory and Policy Analysis: The report should assess the regulatory and policy landscape for Communicable Diseases Drugs, including government incentives, emission standards, and infrastructure development plans. It should analyse the impact of these policies on market growth and provide insights into future regulatory developments.
Recommendations and Conclusion: The report conclude with actionable recommendations for stakeholders, such as Application One Consumer, policymakers, investors, and infrastructure providers. These recommendations should be based on the research findings and address key challenges and opportunities within the Communicable Diseases Drugs market.
Supporting Data and Appendices: The report include supporting data, charts, and graphs to substantiate the analysis and findings. It also includes appendices with additional detailed information, such as data sources, survey questionnaires, and detailed market forecasts.
Market Segmentation
- Communicable Diseases Drugs market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of value.
Market segment by Type
- HIV
- Influenza
- TB
- Malaria
- Hepatitis
- HPV
Market segment by Application
Global Communicable Diseases Drugs Market Segment Percentages, By Region and Country, 2023 (%)
- North America
- US
- Canada
- Mexico
- Europe
- Germany
- France
- U.K.
- Italy
- Russia
- Nordic Countries
- Benelux
- Rest of Europe
- Asia
- China
- Japan
- South Korea
- Southeast Asia
- India
- Rest of Asia
- South America
- Brazil
- Argentina
- Rest of South America
- Middle East & Africa
- Turkey
- Israel
- Saudi Arabia
- UAE
- Rest of Middle East & Africa
Major players covered
- Novartis
- Gilead
- GSK
- Roche
- Merck
- Boehringer Ingelheim
- Eli Lilly
- AstraZeneca
- J & J
- Teva
- AbbVie
- Bausch Health
- Abbott
- Sanofi
- Sun Pharma
- Endo
- Apotex
- Amneal Pharma
- Torrent Pharma
Outline of Major Chapters:
Chapter 1: Introduces the definition of Communicable Diseases Drugs, market overview.
Chapter 2: Global Communicable Diseases Drugs market size in revenue.
Chapter 3: Detailed analysis of Communicable Diseases Drugs company competitive landscape, revenue and market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Communicable Diseases Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: The main points and conclusions of the report.
| Report Attributes |
Report Details |
| Report Title |
Communicable Diseases Drugs Market, Global Outlook and Forecast 2024-2030 |
| Market size in 2023 |
US$ 26560 million
|
| Forecast Market size by 2030 |
US$ 65970 million
|
| Growth Rate |
CAGR of 6.9% |
| Historical Year |
2018 to 2022 (Data from 2010 can be provided as per availability) |
| Base Year |
2023 |
| Forecast Year |
2031 |
| Number of Pages |
123 Pages |
| Customization Available |
Yes, the report can be customized as per your need. |
TABLE OF CONTENTS
1 Introduction to Research & Analysis Reports
1.1 Communicable Diseases Drugs Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Communicable Diseases Drugs Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Communicable Diseases Drugs Overall Market Size
2.1 Global Communicable Diseases Drugs Market Size: 2023 VS 2030
2.2 Global Communicable Diseases Drugs Market Size, Prospects & Forecasts: 2019-2030
2.3 Key Market Trends, Opportunity, Drivers and Restraints
2.3.1 Market Opportunities & Trends
2.3.2 Market Drivers
2.3.3 Market Restraints
3 Company Landscape
3.1 Top Communicable Diseases Drugs Players in Global Market
3.2 Top Global Communicable Diseases Drugs Companies Ranked by Revenue
3.3 Global Communicable Diseases Drugs Revenue by Companies
3.4 Top 3 and Top 5 Communicable Diseases Drugs Companies in Global Market, by Revenue in 2023
3.5 Global Companies Communicable Diseases Drugs Product Type
3.6 Tier 1, Tier 2 and Tier 3 Communicable Diseases Drugs Players in Global Market
3.6.1 List of Global Tier 1 Communicable Diseases Drugs Companies
3.6.2 List of Global Tier 2 and Tier 3 Communicable Diseases Drugs Companies
4 Market Sights by Product
4.1 Overview
4.1.1 By Type - Global Communicable Diseases Drugs Market Size Markets, 2023 & 2030
4.1.2 HIV
4.1.3 Influenza
4.1.4 TB
4.1.5 Malaria
4.1.6 Hepatitis
4.1.7 HPV
4.2 By Type - Global Communicable Diseases Drugs Revenue & Forecasts
4.2.1 By Type - Global Communicable Diseases Drugs Revenue, 2019-2024
4.2.2 By Type - Global Communicable Diseases Drugs Revenue, 2025-2030
4.2.3 By Type - Global Communicable Diseases Drugs Revenue Market Share, 2019-2030
5 Sights by Application
5.1 Overview
5.1.1 By Application - Global Communicable Diseases Drugs Market Size, 2023 & 2030
5.1.2 Hospital
5.1.3 Clinic
5.1.4 Other
5.2 By Application - Global Communicable Diseases Drugs Revenue & Forecasts
5.2.1 By Application - Global Communicable Diseases Drugs Revenue, 2019-2024
5.2.2 By Application - Global Communicable Diseases Drugs Revenue, 2025-2030
5.2.3 By Application - Global Communicable Diseases Drugs Revenue Market Share, 2019-2030
6 Sights by Region
6.1 By Region - Global Communicable Diseases Drugs Market Size, 2023 & 2030
6.2 By Region - Global Communicable Diseases Drugs Revenue & Forecasts
6.2.1 By Region - Global Communicable Diseases Drugs Revenue, 2019-2024
6.2.2 By Region - Global Communicable Diseases Drugs Revenue, 2025-2030
6.2.3 By Region - Global Communicable Diseases Drugs Revenue Market Share, 2019-2030
6.3 North America
6.3.1 By Country - North America Communicable Diseases Drugs Revenue, 2019-2030
6.3.2 US Communicable Diseases Drugs Market Size, 2019-2030
6.3.3 Canada Communicable Diseases Drugs Market Size, 2019-2030
6.3.4 Mexico Communicable Diseases Drugs Market Size, 2019-2030
6.4 Europe
6.4.1 By Country - Europe Communicable Diseases Drugs Revenue, 2019-2030
6.4.2 Germany Communicable Diseases Drugs Market Size, 2019-2030
6.4.3 France Communicable Diseases Drugs Market Size, 2019-2030
6.4.4 U.K. Communicable Diseases Drugs Market Size, 2019-2030
6.4.5 Italy Communicable Diseases Drugs Market Size, 2019-2030
6.4.6 Russia Communicable Diseases Drugs Market Size, 2019-2030
6.4.7 Nordic Countries Communicable Diseases Drugs Market Size, 2019-2030
6.4.8 Benelux Communicable Diseases Drugs Market Size, 2019-2030
6.5 Asia
6.5.1 By Region - Asia Communicable Diseases Drugs Revenue, 2019-2030
6.5.2 China Communicable Diseases Drugs Market Size, 2019-2030
6.5.3 Japan Communicable Diseases Drugs Market Size, 2019-2030
6.5.4 South Korea Communicable Diseases Drugs Market Size, 2019-2030
6.5.5 Southeast Asia Communicable Diseases Drugs Market Size, 2019-2030
6.5.6 India Communicable Diseases Drugs Market Size, 2019-2030
6.6 South America
6.6.1 By Country - South America Communicable Diseases Drugs Revenue, 2019-2030
6.6.2 Brazil Communicable Diseases Drugs Market Size, 2019-2030
6.6.3 Argentina Communicable Diseases Drugs Market Size, 2019-2030
6.7 Middle East & Africa
6.7.1 By Country - Middle East & Africa Communicable Diseases Drugs Revenue, 2019-2030
6.7.2 Turkey Communicable Diseases Drugs Market Size, 2019-2030
6.7.3 Israel Communicable Diseases Drugs Market Size, 2019-2030
6.7.4 Saudi Arabia Communicable Diseases Drugs Market Size, 2019-2030
6.7.5 UAE Communicable Diseases Drugs Market Size, 2019-2030
7 Communicable Diseases Drugs Companies Profiles
7.1 Novartis
7.1.1 Novartis Company Summary
7.1.2 Novartis Business Overview
7.1.3 Novartis Communicable Diseases Drugs Major Product Offerings
7.1.4 Novartis Communicable Diseases Drugs Revenue in Global Market (2019-2024)
7.1.5 Novartis Key News & Latest Developments
7.2 Gilead
7.2.1 Gilead Company Summary
7.2.2 Gilead Business Overview
7.2.3 Gilead Communicable Diseases Drugs Major Product Offerings
7.2.4 Gilead Communicable Diseases Drugs Revenue in Global Market (2019-2024)
7.2.5 Gilead Key News & Latest Developments
7.3 GSK
7.3.1 GSK Company Summary
7.3.2 GSK Business Overview
7.3.3 GSK Communicable Diseases Drugs Major Product Offerings
7.3.4 GSK Communicable Diseases Drugs Revenue in Global Market (2019-2024)
7.3.5 GSK Key News & Latest Developments
7.4 Roche
7.4.1 Roche Company Summary
7.4.2 Roche Business Overview
7.4.3 Roche Communicable Diseases Drugs Major Product Offerings
7.4.4 Roche Communicable Diseases Drugs Revenue in Global Market (2019-2024)
7.4.5 Roche Key News & Latest Developments
7.5 Merck
7.5.1 Merck Company Summary
7.5.2 Merck Business Overview
7.5.3 Merck Communicable Diseases Drugs Major Product Offerings
7.5.4 Merck Communicable Diseases Drugs Revenue in Global Market (2019-2024)
7.5.5 Merck Key News & Latest Developments
7.6 Boehringer Ingelheim
7.6.1 Boehringer Ingelheim Company Summary
7.6.2 Boehringer Ingelheim Business Overview
7.6.3 Boehringer Ingelheim Communicable Diseases Drugs Major Product Offerings
7.6.4 Boehringer Ingelheim Communicable Diseases Drugs Revenue in Global Market (2019-2024)
7.6.5 Boehringer Ingelheim Key News & Latest Developments
7.7 Eli Lilly
7.7.1 Eli Lilly Company Summary
7.7.2 Eli Lilly Business Overview
7.7.3 Eli Lilly Communicable Diseases Drugs Major Product Offerings
7.7.4 Eli Lilly Communicable Diseases Drugs Revenue in Global Market (2019-2024)
7.7.5 Eli Lilly Key News & Latest Developments
7.8 AstraZeneca
7.8.1 AstraZeneca Company Summary
7.8.2 AstraZeneca Business Overview
7.8.3 AstraZeneca Communicable Diseases Drugs Major Product Offerings
7.8.4 AstraZeneca Communicable Diseases Drugs Revenue in Global Market (2019-2024)
7.8.5 AstraZeneca Key News & Latest Developments
7.9 J & J
7.9.1 J & J Company Summary
7.9.2 J & J Business Overview
7.9.3 J & J Communicable Diseases Drugs Major Product Offerings
7.9.4 J & J Communicable Diseases Drugs Revenue in Global Market (2019-2024)
7.9.5 J & J Key News & Latest Developments
7.10 Teva
7.10.1 Teva Company Summary
7.10.2 Teva Business Overview
7.10.3 Teva Communicable Diseases Drugs Major Product Offerings
7.10.4 Teva Communicable Diseases Drugs Revenue in Global Market (2019-2024)
7.10.5 Teva Key News & Latest Developments
7.11 AbbVie
7.11.1 AbbVie Company Summary
7.11.2 AbbVie Business Overview
7.11.3 AbbVie Communicable Diseases Drugs Major Product Offerings
7.11.4 AbbVie Communicable Diseases Drugs Revenue in Global Market (2019-2024)
7.11.5 AbbVie Key News & Latest Developments
7.12 Bausch Health
7.12.1 Bausch Health Company Summary
7.12.2 Bausch Health Business Overview
7.12.3 Bausch Health Communicable Diseases Drugs Major Product Offerings
7.12.4 Bausch Health Communicable Diseases Drugs Revenue in Global Market (2019-2024)
7.12.5 Bausch Health Key News & Latest Developments
7.13 Abbott
7.13.1 Abbott Company Summary
7.13.2 Abbott Business Overview
7.13.3 Abbott Communicable Diseases Drugs Major Product Offerings
7.13.4 Abbott Communicable Diseases Drugs Revenue in Global Market (2019-2024)
7.13.5 Abbott Key News & Latest Developments
7.14 Sanofi
7.14.1 Sanofi Company Summary
7.14.2 Sanofi Business Overview
7.14.3 Sanofi Communicable Diseases Drugs Major Product Offerings
7.14.4 Sanofi Communicable Diseases Drugs Revenue in Global Market (2019-2024)
7.14.5 Sanofi Key News & Latest Developments
7.15 Sun Pharma
7.15.1 Sun Pharma Company Summary
7.15.2 Sun Pharma Business Overview
7.15.3 Sun Pharma Communicable Diseases Drugs Major Product Offerings
7.15.4 Sun Pharma Communicable Diseases Drugs Revenue in Global Market (2019-2024)
7.15.5 Sun Pharma Key News & Latest Developments
7.16 Endo
7.16.1 Endo Company Summary
7.16.2 Endo Business Overview
7.16.3 Endo Communicable Diseases Drugs Major Product Offerings
7.16.4 Endo Communicable Diseases Drugs Revenue in Global Market (2019-2024)
7.16.5 Endo Key News & Latest Developments
7.17 Apotex
7.17.1 Apotex Company Summary
7.17.2 Apotex Business Overview
7.17.3 Apotex Communicable Diseases Drugs Major Product Offerings
7.17.4 Apotex Communicable Diseases Drugs Revenue in Global Market (2019-2024)
7.17.5 Apotex Key News & Latest Developments
7.18 Amneal Pharma
7.18.1 Amneal Pharma Company Summary
7.18.2 Amneal Pharma Business Overview
7.18.3 Amneal Pharma Communicable Diseases Drugs Major Product Offerings
7.18.4 Amneal Pharma Communicable Diseases Drugs Revenue in Global Market (2019-2024)
7.18.5 Amneal Pharma Key News & Latest Developments
7.19 Torrent Pharma
7.19.1 Torrent Pharma Company Summary
7.19.2 Torrent Pharma Business Overview
7.19.3 Torrent Pharma Communicable Diseases Drugs Major Product Offerings
7.19.4 Torrent Pharma Communicable Diseases Drugs Revenue in Global Market (2019-2024)
7.19.5 Torrent Pharma Key News & Latest Developments
8 Conclusion
9 Appendix
9.1 Note
9.2 Examples of Clients
9.3 Disclaimer
LIST OF TABLES & FIGURES
List of Tables
Table 1. Communicable Diseases Drugs Market Opportunities & Trends in Global Market
Table 2. Communicable Diseases Drugs Market Drivers in Global Market
Table 3. Communicable Diseases Drugs Market Restraints in Global Market
Table 4. Key Players of Communicable Diseases Drugs in Global Market
Table 5. Top Communicable Diseases Drugs Players in Global Market, Ranking by Revenue (2023)
Table 6. Global Communicable Diseases Drugs Revenue by Companies, (US$, Mn), 2019-2024
Table 7. Global Communicable Diseases Drugs Revenue Share by Companies, 2019-2024
Table 8. Global Companies Communicable Diseases Drugs Product Type
Table 9. List of Global Tier 1 Communicable Diseases Drugs Companies, Revenue (US$, Mn) in 2023 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Communicable Diseases Drugs Companies, Revenue (US$, Mn) in 2023 and Market Share
Table 11. By Type ? Global Communicable Diseases Drugs Revenue, (US$, Mn), 2023 & 2030
Table 12. By Type - Communicable Diseases Drugs Revenue in Global (US$, Mn), 2019-2024
Table 13. By Type - Communicable Diseases Drugs Revenue in Global (US$, Mn), 2025-2030
Table 14. By Application ? Global Communicable Diseases Drugs Revenue, (US$, Mn), 2023 & 2030
Table 15. By Application - Communicable Diseases Drugs Revenue in Global (US$, Mn), 2019-2024
Table 16. By Application - Communicable Diseases Drugs Revenue in Global (US$, Mn), 2025-2030
Table 17. By Region ? Global Communicable Diseases Drugs Revenue, (US$, Mn), 2023 & 2030
Table 18. By Region - Global Communicable Diseases Drugs Revenue (US$, Mn), 2019-2024
Table 19. By Region - Global Communicable Diseases Drugs Revenue (US$, Mn), 2025-2030
Table 20. By Country - North America Communicable Diseases Drugs Revenue, (US$, Mn), 2019-2024
Table 21. By Country - North America Communicable Diseases Drugs Revenue, (US$, Mn), 2025-2030
Table 22. By Country - Europe Communicable Diseases Drugs Revenue, (US$, Mn), 2019-2024
Table 23. By Country - Europe Communicable Diseases Drugs Revenue, (US$, Mn), 2025-2030
Table 24. By Region - Asia Communicable Diseases Drugs Revenue, (US$, Mn), 2019-2024
Table 25. By Region - Asia Communicable Diseases Drugs Revenue, (US$, Mn), 2025-2030
Table 26. By Country - South America Communicable Diseases Drugs Revenue, (US$, Mn), 2019-2024
Table 27. By Country - South America Communicable Diseases Drugs Revenue, (US$, Mn), 2025-2030
Table 28. By Country - Middle East & Africa Communicable Diseases Drugs Revenue, (US$, Mn), 2019-2024
Table 29. By Country - Middle East & Africa Communicable Diseases Drugs Revenue, (US$, Mn), 2025-2030
Table 30. Novartis Company Summary
Table 31. Novartis Communicable Diseases Drugs Product Offerings
Table 32. Novartis Communicable Diseases Drugs Revenue (US$, Mn) & (2019-2024)
Table 33. Novartis Key News & Latest Developments
Table 34. Gilead Company Summary
Table 35. Gilead Communicable Diseases Drugs Product Offerings
Table 36. Gilead Communicable Diseases Drugs Revenue (US$, Mn) & (2019-2024)
Table 37. Gilead Key News & Latest Developments
Table 38. GSK Company Summary
Table 39. GSK Communicable Diseases Drugs Product Offerings
Table 40. GSK Communicable Diseases Drugs Revenue (US$, Mn) & (2019-2024)
Table 41. GSK Key News & Latest Developments
Table 42. Roche Company Summary
Table 43. Roche Communicable Diseases Drugs Product Offerings
Table 44. Roche Communicable Diseases Drugs Revenue (US$, Mn) & (2019-2024)
Table 45. Roche Key News & Latest Developments
Table 46. Merck Company Summary
Table 47. Merck Communicable Diseases Drugs Product Offerings
Table 48. Merck Communicable Diseases Drugs Revenue (US$, Mn) & (2019-2024)
Table 49. Merck Key News & Latest Developments
Table 50. Boehringer Ingelheim Company Summary
Table 51. Boehringer Ingelheim Communicable Diseases Drugs Product Offerings
Table 52. Boehringer Ingelheim Communicable Diseases Drugs Revenue (US$, Mn) & (2019-2024)
Table 53. Boehringer Ingelheim Key News & Latest Developments
Table 54. Eli Lilly Company Summary
Table 55. Eli Lilly Communicable Diseases Drugs Product Offerings
Table 56. Eli Lilly Communicable Diseases Drugs Revenue (US$, Mn) & (2019-2024)
Table 57. Eli Lilly Key News & Latest Developments
Table 58. AstraZeneca Company Summary
Table 59. AstraZeneca Communicable Diseases Drugs Product Offerings
Table 60. AstraZeneca Communicable Diseases Drugs Revenue (US$, Mn) & (2019-2024)
Table 61. AstraZeneca Key News & Latest Developments
Table 62. J & J Company Summary
Table 63. J & J Communicable Diseases Drugs Product Offerings
Table 64. J & J Communicable Diseases Drugs Revenue (US$, Mn) & (2019-2024)
Table 65. J & J Key News & Latest Developments
Table 66. Teva Company Summary
Table 67. Teva Communicable Diseases Drugs Product Offerings
Table 68. Teva Communicable Diseases Drugs Revenue (US$, Mn) & (2019-2024)
Table 69. Teva Key News & Latest Developments
Table 70. AbbVie Company Summary
Table 71. AbbVie Communicable Diseases Drugs Product Offerings
Table 72. AbbVie Communicable Diseases Drugs Revenue (US$, Mn) & (2019-2024)
Table 73. AbbVie Key News & Latest Developments
Table 74. Bausch Health Company Summary
Table 75. Bausch Health Communicable Diseases Drugs Product Offerings
Table 76. Bausch Health Communicable Diseases Drugs Revenue (US$, Mn) & (2019-2024)
Table 77. Bausch Health Key News & Latest Developments
Table 78. Abbott Company Summary
Table 79. Abbott Communicable Diseases Drugs Product Offerings
Table 80. Abbott Communicable Diseases Drugs Revenue (US$, Mn) & (2019-2024)
Table 81. Abbott Key News & Latest Developments
Table 82. Sanofi Company Summary
Table 83. Sanofi Communicable Diseases Drugs Product Offerings
Table 84. Sanofi Communicable Diseases Drugs Revenue (US$, Mn) & (2019-2024)
Table 85. Sanofi Key News & Latest Developments
Table 86. Sun Pharma Company Summary
Table 87. Sun Pharma Communicable Diseases Drugs Product Offerings
Table 88. Sun Pharma Communicable Diseases Drugs Revenue (US$, Mn) & (2019-2024)
Table 89. Sun Pharma Key News & Latest Developments
Table 90. Endo Company Summary
Table 91. Endo Communicable Diseases Drugs Product Offerings
Table 92. Endo Communicable Diseases Drugs Revenue (US$, Mn) & (2019-2024)
Table 93. Endo Key News & Latest Developments
Table 94. Apotex Company Summary
Table 95. Apotex Communicable Diseases Drugs Product Offerings
Table 96. Apotex Communicable Diseases Drugs Revenue (US$, Mn) & (2019-2024)
Table 97. Apotex Key News & Latest Developments
Table 98. Amneal Pharma Company Summary
Table 99. Amneal Pharma Communicable Diseases Drugs Product Offerings
Table 100. Amneal Pharma Communicable Diseases Drugs Revenue (US$, Mn) & (2019-2024)
Table 101. Amneal Pharma Key News & Latest Developments
Table 102. Torrent Pharma Company Summary
Table 103. Torrent Pharma Communicable Diseases Drugs Product Offerings
Table 104. Torrent Pharma Communicable Diseases Drugs Revenue (US$, Mn) & (2019-2024)
Table 105. Torrent Pharma Key News & Latest Developments
List of Figures
Figure 1. Communicable Diseases Drugs Segment by Type in 2023
Figure 2. Communicable Diseases Drugs Segment by Application in 2023
Figure 3. Global Communicable Diseases Drugs Market Overview: 2023
Figure 4. Key Caveats
Figure 5. Global Communicable Diseases Drugs Market Size: 2023 VS 2030 (US$, Mn)
Figure 6. Global Communicable Diseases Drugs Revenue, 2019-2030 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by Communicable Diseases Drugs Revenue in 2023
Figure 8. By Type - Global Communicable Diseases Drugs Revenue Market Share, 2019-2030
Figure 9. By Application - Global Communicable Diseases Drugs Revenue Market Share, 2019-2030
Figure 10. By Type - Global Communicable Diseases Drugs Revenue, (US$, Mn), 2023 & 2030
Figure 11. By Type - Global Communicable Diseases Drugs Revenue Market Share, 2019-2030
Figure 12. By Application - Global Communicable Diseases Drugs Revenue, (US$, Mn), 2023 & 2030
Figure 13. By Application - Global Communicable Diseases Drugs Revenue Market Share, 2019-2030
Figure 14. By Region - Global Communicable Diseases Drugs Revenue Market Share, 2019-2030
Figure 15. By Country - North America Communicable Diseases Drugs Revenue Market Share, 2019-2030
Figure 16. US Communicable Diseases Drugs Revenue, (US$, Mn), 2019-2030
Figure 17. Canada Communicable Diseases Drugs Revenue, (US$, Mn), 2019-2030
Figure 18. Mexico Communicable Diseases Drugs Revenue, (US$, Mn), 2019-2030
Figure 19. By Country - Europe Communicable Diseases Drugs Revenue Market Share, 2019-2030
Figure 20. Germany Communicable Diseases Drugs Revenue, (US$, Mn), 2019-2030
Figure 21. France Communicable Diseases Drugs Revenue, (US$, Mn), 2019-2030
Figure 22. U.K. Communicable Diseases Drugs Revenue, (US$, Mn), 2019-2030
Figure 23. Italy Communicable Diseases Drugs Revenue, (US$, Mn), 2019-2030
Figure 24. Russia Communicable Diseases Drugs Revenue, (US$, Mn), 2019-2030
Figure 25. Nordic Countries Communicable Diseases Drugs Revenue, (US$, Mn), 2019-2030
Figure 26. Benelux Communicable Diseases Drugs Revenue, (US$, Mn), 2019-2030
Figure 27. By Region - Asia Communicable Diseases Drugs Revenue Market Share, 2019-2030
Figure 28. China Communicable Diseases Drugs Revenue, (US$, Mn), 2019-2030
Figure 29. Japan Communicable Diseases Drugs Revenue, (US$, Mn), 2019-2030
Figure 30. South Korea Communicable Diseases Drugs Revenue, (US$, Mn), 2019-2030
Figure 31. Southeast Asia Communicable Diseases Drugs Revenue, (US$, Mn), 2019-2030
Figure 32. India Communicable Diseases Drugs Revenue, (US$, Mn), 2019-2030
Figure 33. By Country - South America Communicable Diseases Drugs Revenue Market Share, 2019-2030
Figure 34. Brazil Communicable Diseases Drugs Revenue, (US$, Mn), 2019-2030
Figure 35. Argentina Communicable Diseases Drugs Revenue, (US$, Mn), 2019-2030
Figure 36. By Country - Middle East & Africa Communicable Diseases Drugs Revenue Market Share, 2019-2030
Figure 37. Turkey Communicable Diseases Drugs Revenue, (US$, Mn), 2019-2030
Figure 38. Israel Communicable Diseases Drugs Revenue, (US$, Mn), 2019-2030
Figure 39. Saudi Arabia Communicable Diseases Drugs Revenue, (US$, Mn), 2019-2030
Figure 40. UAE Communicable Diseases Drugs Revenue, (US$, Mn), 2019-2030
Figure 41. Novartis Communicable Diseases Drugs Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 42. Gilead Communicable Diseases Drugs Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 43. GSK Communicable Diseases Drugs Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 44. Roche Communicable Diseases Drugs Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 45. Merck Communicable Diseases Drugs Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 46. Boehringer Ingelheim Communicable Diseases Drugs Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 47. Eli Lilly Communicable Diseases Drugs Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 48. AstraZeneca Communicable Diseases Drugs Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 49. J & J Communicable Diseases Drugs Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 50. Teva Communicable Diseases Drugs Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 51. AbbVie Communicable Diseases Drugs Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 52. Bausch Health Communicable Diseases Drugs Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 53. Abbott Communicable Diseases Drugs Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 54. Sanofi Communicable Diseases Drugs Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 55. Sun Pharma Communicable Diseases Drugs Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 56. Endo Communicable Diseases Drugs Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 57. Apotex Communicable Diseases Drugs Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 58. Amneal Pharma Communicable Diseases Drugs Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 59. Torrent Pharma Communicable Diseases Drugs Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
